Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.5.1873

High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment  

Fateh, Abolfazl (Department of Virology, School of Public Health, Tehran University of Medical Sciences)
Aghasadeghi, Mohammad Reza (Department of Hepatitis and AIDS, Pasteur Institute of Iran)
Keyvani, Hossein (Departments of Virology, Iran University of Medical Sciences)
Mollaie, Hamid Reza (Departments of Virology, Iran University of Medical Sciences)
Yari, Shamsi (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran)
Tasbiti, Ali Reza Hadizade (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran)
Ghazanfari, Morteza (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran)
Monavari, Seyed Hamid Reza (Departments of Virology, Iran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.5, 2015 , pp. 1873-1880 More about this Journal
Abstract
Background: A recent genome-wide association study (GWAS) on patients with chronic hepatitis C (CHC) treated with peginterferon and ribavirin (pegIFN-${\alpha}$/RBV) identified a single nucleotide polymorphism (SNP) on chromosome 19 (rs12979860) which was strongly associated with a sustained virological response (SVR). The aim of this study was twofold: to study the relationship between IL28B rs12979860 and sustained virological response (SVR) to pegIFN-${\alpha}$/RVB therapy among CHC patients and to detect the rs12979860 polymorphism by high resolution melting curve (HRM) assay as a simple, fast, sensitive, and inexpensive method. Materials and Methods: The study examined outcomes in 100 patients with chronic hepatitis C in 2 provinces of Iran from December 2011 to June 2013. Two methods were applied to detect IL28B polymorphisms: PCR-sequencing as a gold standard method and HRM as a simple, fast, sensitive, and inexpensive method. Results: The frequencies of IL28B rs12979860 CC, CT, and TT alleles in chronic hepatitis C genotype 1a patients were 10% (10/100), 35% (35/100), and 6% (6/100) and in genotype 3a were 13% (13/100), 31% (31/100), and 5% (5/100), respectively. In genotype 3a infected patients, rs12979860 (CC and CT alleles) and in genotype 1a infected patients (CC allele) were significantly associated with a sustained virological response (SVR). The SVR rates for CC, CT and TT (IL28B rs12979860) were 18%, 34% and 4%, respectively. Multiple logistic regression analysis identified two independent factors that were significantly associated with SVR: IL-28B genotype (rs 12979860 CC vs TT and CT; odds ratio [ORs], 7.86 and 4.084, respectively), and HCV subtype 1a (OR, 7.46). In the present study, an association between SVR rates and IL28B polymorphisms was observed. Conclusions: The HRM assay described herein is rapid, inexpensive, sensitive and accurate for detecting rs12979860 alleles in CHC patients. This method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be clinically beneficial in predicting treatment response in HCV genotype 1 and 3 infected patients. In addition, it was demonstrated that CC and CT alleles in HCV-3a and the CC allele in HCV-1a were significantly associated with response to pegIFN-${\alpha}$/RBV treatment. The present results may help identify subjects for whom the therapy might be successful.
Keywords
Chronic hepatitis C; single nucleotide polymorphism; sustained virological response;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Sharafi H, Pouryasin A, Alavian SM, et al (2012). Development and validation of a simple, rapid and inexpensive PCR-RFLP Method for genotyping of common IL28B polymorphisms: A useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon, 12, 190-5.
2 Shi X, Pan Y, Wang M, et al (2012). IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One, 7, 37054.   DOI
3 Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.   DOI   ScienceOn
4 Suppiah V, Moldovan M, Ahlenstiel G, et al (2009). IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet, 41, 1100-4.   DOI   ScienceOn
5 Thomas DL, Thio CL, Martin MP, et al (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461, 798-801.   DOI
6 Tsubota A, Kiyotaka F, Yoshihisa N, et al (2011). Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol, 17, 419-432.   DOI
7 Viazov S, Kuzin S, Paladi N, et al (1997). Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol, 53, 36-40.   DOI
8 Wohnsland A, Hofmann WP, Sarrazin C (2007). Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev, 20, 23-38.   DOI
9 Yang JD, Roberts LR (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol, 7, 448-58.   DOI
10 Zali MR, Mayumi M, Raoufi M, et al (2000). Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J, 6, 372-7.
11 Zekri AR, Salama H, Medhat E, et al (2014). IL28B rs12979860 Gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev, 15, 7213-8.   DOI
12 Altuglu I, Soyler I, Ozacar T, et al (2008). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis, 12, 239-44.   DOI
13 Afshar RM, Mollaie HR (2012). Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3657-61.   DOI   ScienceOn
14 Akkarathamrongsin S, Thong VD, Payungporn S, et al (2014). IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol, 86, 1482-90.   DOI
15 Alavian SM, Tabatabaei SV, Keshvari M, et al (2010). Peginterferon alpha-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: a singlecentre study of 367 cases. Liver Int, 30, 1173-80.   DOI
16 Antaki N, Craxi A, Kamal S, et al (2010). Theneglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int, 30, 342-55.   DOI
17 Chen X, Sullivan PF (2003). Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J, 3, 77-96.   DOI
18 Asselah T, Bieche I, Paradis V, et al (2007). Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis, 27, 13-27.   DOI
19 Balagopal A, Thomas DL, Thio CL (2010). IL28B and the control of hepatitis C virus infection. Gastroenterology, 139, 1865-76.   DOI
20 Beinhardt S, Rutter K, Stattermayer AF, Ferenci P (2013). Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis, 56, 118-122.   DOI
21 Dai CY, Huang JF, Hsieh MY, et al (2009). Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol, 50, 712-8.   DOI
22 Domagalski K, Pawlowska M, Tretyn A, et al (2013). Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis, 32, 745-54.   DOI
23 Eslam M, Leung R, Romero-Gomez M, et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol, 61, 235-41.   DOI
24 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. From: http://www.easl.eu/_newsroom/latest-news/easlrecommendations-on-treatment-of-hepatitis-c-2014
25 Falleti E, Bitetto D, Fabris C, et al (2011). Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol, 31, 891-9.   DOI
26 Grebely J, Petoumenos K, Hellard M, et al (2010). Potential role for interleukin-28B genotype in treatment decisionmaking in recent hepatitis C virus infection. Hepatology, 52, 1216-24.   DOI
27 Ge D, Fellay J, Thompson AJ, et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399-401   DOI
28 Ghany MG, Nelson DR, Strader DB, et al (2011). American association for study of liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-44.   DOI
29 Ghany MG, Strader DB, Thomas DL, Seeff LB (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49, 1335-74.   DOI
30 Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51.   DOI
31 Keyvani H, Alizadeh AH, Alavian SM, et al (2007). Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res, 37, 101-3.   DOI
32 Keyvani H, Fazlalipour M, Monavari SH, et al (2012). Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5931-49.
33 Mangia A, Thompson AJ, Santoro R, et al (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 139, 821-7.   DOI   ScienceOn
34 Martinez-Gomez LE, Chavez-Tapia NC, Burguete-Garcia AI, et al (2012). IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol, 11, 876-81.
35 Poon KS, Ho SS, Tang JW, et al (2012). Targeting both rs12979860 and rs8099917 polymorphisms with a singletube high-resolution melting assay for IL28b genotyping. J Clin Microbiol, 50, 3353-5.   DOI
36 Melis R, Fauron C, McMillin G, et al (2011). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13, 446-51.   DOI
37 Moghaddam A, Melum E, Reinton N, et al (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology, 53, 746-54.   DOI
38 Namazee N, Sali S, Asadi S, et al (2012). Real response to therapy in chronic hepatitis C virus patients: a study from Iran. Hepat Mon, 12, 6151.
39 Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
40 Rauch A, Kutalik Z, Descombes P, et al (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338-45.   DOI   ScienceOn
41 Sajid A, Ayaz A, Raham Sh, et al. Genotyping of HCV RNA Reveals That 3a Is the Most Prevalent Genotype in Mardan, Pakistan. Advances in Virology, 2014, 1-5.
42 Samimi-Rad K, Nategh R, Malekzadeh R, et al (2004). Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol, 74, 246-52.   DOI
43 Sarrazin C, Susser S, Doehring A, et al (2011). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol, 54, 415-21.   DOI